Agzew Yeshitila
Department of Internal Medicine, Brandon Regional Hospital, Brandon, Florida, USA.
Clin Cardiol. 2009 Jan;32(1):15-20. doi: 10.1002/clc.20445.
Cardiac troponins (CTn) are the most sensitive and specific biochemical markers of myocardial injury and risk stratification. The assay for troponin T (cTnI) is standardized, and results obtained from different institutions are comparable. This is not the case with troponin I (cTnT), and clinicians should be aware that each institution must analyze and standardize its own results. Elevated cTn levels indicate cardiac injury, but do not define the mechanical injury. The differentiation of cTn elevation caused by coronary events from those not related to an acute coronary syndrome (ACS) is tiresome, at times vexing, and often costly. Elevation of cTn in non-ACS is a marker of increased cardiac and all-cause morbidity and mortality. The cause of these elevations may involve serious medical conditions that require meticulous diagnostic evaluation and aggressive therapy. At present, there are no guidelines to treat patients with elevated troponin levels and no coronary disease. The current strategy of treatment of patients with elevated troponin and non-ACS involves treating the underlying causes.
心肌肌钙蛋白(CTn)是心肌损伤和风险分层最敏感、特异的生化标志物。肌钙蛋白T(cTnI)检测已标准化,不同机构获得的结果具有可比性。肌钙蛋白I(cTnT)则不然,临床医生应意识到每个机构必须分析并标准化自身的检测结果。肌钙蛋白水平升高表明存在心脏损伤,但不能确定机械性损伤。区分由冠状动脉事件导致的肌钙蛋白升高与非急性冠状动脉综合征(ACS)相关的升高既繁琐,有时又令人烦恼,且往往成本高昂。非ACS患者肌钙蛋白升高是心脏发病率和全因死亡率增加的标志。这些升高的原因可能涉及需要细致诊断评估和积极治疗的严重疾病。目前,尚无针对肌钙蛋白水平升高且无冠心病患者的治疗指南。当前对肌钙蛋白升高且无ACS患者的治疗策略是治疗潜在病因。